Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
12/2002
12/12/2002WO2002098376A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
12/12/2002WO2002098362A2 Use of rank antagonists to treat cancer
12/12/2002WO2002098356A2 Ppp2cs as modifiers of the p53 pathway and methods of use
12/12/2002WO2002098354A2 Compositions and methods for inhibiting bone resorption
12/12/2002WO2002098352A2 PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
12/12/2002WO2002098347A2 Methods and compositions that affect melanogenesis (pfi-016cip/pct)
12/12/2002WO2002098278A2 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002WO2002098232A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002WO2002089848A3 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
12/12/2002WO2002089805A3 Use of regularly scheduled high dose intravenous methotrexate therapy
12/12/2002WO2002082044A3 Method of imaging cell death in vivo
12/12/2002WO2002080890A3 A jasmonate pharmaceutical composition for treatment of cancer
12/12/2002WO2002079232A3 Reducing the immunogenicity of fusion proteins
12/12/2002WO2002076494A3 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
12/12/2002WO2002074756A3 Urokinase inhibitors
12/12/2002WO2002072078A3 Use of sugar phosphates, amino acids, amino acid analogs, e.g. carbomethoxypropionyl cyanide for reducing weight or diabetes complications
12/12/2002WO2002068015A9 Modular infusion device and method
12/12/2002WO2002062297A9 Methods and compositions for modulating gluconeogenesis using pgc-1
12/12/2002WO2002059612A3 Animal model and cell-line expressing modified chlorine channel
12/12/2002WO2002058620A3 Pharmaceutical compositions containing a cox-ii inhibitor and a muscle relaxant
12/12/2002WO2002050106A3 Compositions and methods involving an essential staphylococcus aureus gene and its encoded protein staau_r4
12/12/2002WO2002046404A3 Schizophrenia-related voltage-gated ion channel gene and protein
12/12/2002WO2002044718A3 S.aureus protein staau r2, gene encoding it and uses thereof
12/12/2002WO2002036163A3 Novel medicament compositions consisting of tiotropium salts and antihistamines for treating respiratory illnesses
12/12/2002WO2002032898A3 Novel anticholinergics, method for the production thereof and use thereof as medicaments
12/12/2002WO2002029044A3 Modulation of the transcription of pro-inflammatory gene products
12/12/2002WO2002024749A3 Isolated human transporter proteins, nucleic acid molecules encoding them, and uses thereof
12/12/2002WO2002018593A3 Modulation of fas and fasl expression
12/12/2002WO2002018557A3 Human kinases
12/12/2002WO2002008292A3 Human monoclonal antibody against hepatitis c virus e2 glycoprotein
12/12/2002WO2002002077A3 Liposomal antineoplastic drugs and uses thereof
12/12/2002WO2001097850A3 Combinations and compositions which interfere with vegf/vegf and angiopoietin/tie receptor function and their use (ii)
12/12/2002WO2000032152A3 Compositions and methods for regulating bacterial pathogenesis
12/12/2002US20020188281 Stabilized bioactive preparations and method of use
12/12/2002US20020188139 P-thienylbenzylamides as agonists of angiotensin-(1-7) receptors, and methods of their preparartion and use
12/12/2002US20020188029 Methods of treating or preventing weight gain, obesity, and related disorders
12/12/2002US20020188028 Anti-infective compositions, methods and systems for treating disordered tissue
12/12/2002US20020188012 Method for treating Alzheimer's disease
12/12/2002US20020187999 Anti-inflammatory uses of manzamines
12/12/2002US20020187998 Local ophthalmic agent for treatment of ocular inflammation
12/12/2002US20020187996 Prevention of addiction in pain management
12/12/2002US20020187995 Methods for use in modifying the perception of pain
12/12/2002US20020187992 Prodrugs via acylation with cinnamate
12/12/2002US20020187982 Glucagon antagonists/inverse agonists
12/12/2002US20020187977 Methods for restoring cognitive function following systemic stress
12/12/2002US20020187972 Methods for modulating expression of exogenous genes in mammalian systems
12/12/2002US20020187959 Compositions and methods for treating mammals with modified alginates and modified pectins
12/12/2002US20020187957 Time release reverse transcriptase inhibitors
12/12/2002US20020187956 Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
12/12/2002US20020187954 Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to modulate cell growth
12/12/2002US20020187939 Use of inhibitors of the renin-angiotensin system
12/12/2002US20020187930 Substances and their uses
12/12/2002US20020187534 Treating cancer by increasing intracellular malonyl CoA levels
12/12/2002US20020187523 Extracellular signaling molecules
12/12/2002US20020187519 Treatment regimen for prostate cancer
12/12/2002US20020187499 Kit for use in monitoring and treatment of endometriosis
12/12/2002US20020187235 Ingestible laxative beverage
12/12/2002US20020187204 Diet composition and method of weight management
12/12/2002US20020187197 Templating of solid particles by polymer multilayers
12/12/2002US20020187189 Proliposomal drug delivery system
12/12/2002US20020187181 System for delivering cosmetics and pharmaceuticals
12/12/2002US20020187152 Administering a drug which can selectively kill Fusobacterium varium cells, or a drug which can neutralize the toxin produced by Fusobacterium varium cells; vaccines, diagnosis, screening
12/12/2002US20020187149 Activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptible carrier.
12/12/2002US20020187145 Lysing or blocking unwanted cells with IL-2 receptor-specific binding substance
12/12/2002US20020187144 Useful for treating patients with colorectal cancer and gastric carcinomas; particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.
12/12/2002US20020187130 Simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, especially a phytohemagglutinin, and to generate heat shock protein.
12/12/2002US20020187105 Polymer combinations that result in stabilized aerosols for gene delivery to the lungs
12/12/2002DE10127717A1 Cosmetic or dermatological preparations for combating undesirable skin pigmentation, e.g. in treatment of local hyperpigmentation disorders or cosmetic inhibition of tanning, containing pyridoxine as active agent
12/12/2002DE10127544A1 Photodynamic therapy used for killing tumor cells in humans, by application of light in presence of carbonyl-substituted chlorin compound as oxidation stable photosensitizer
12/12/2002DE10125883A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Nierenersatztherapie Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the context of renal replacement therapy
12/12/2002DE10125882A1 Arzneimittel enthaltend einen Effektor des Glutathionmetabolismus zusammen mit alpha-Liponsäure im Rahmen der Behandlung des Diabetes mellitus Medicines containing an effector of the glutathione metabolism together with alpha-lipoic acid in the treatment of diabetes mellitus
12/12/2002CA2450009A1 Method and apparatus for treating tumors using low strength electric fields
12/12/2002CA2449940A1 Bcl-2 dnazymes
12/12/2002CA2449770A1 Novel anti-infectives
12/12/2002CA2449752A1 Method of identifying a polymorphism in cyp2d6
12/12/2002CA2449671A1 Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
12/12/2002CA2449658A1 Use of rank antagonists to treat cancer
12/12/2002CA2449487A1 Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
12/12/2002CA2449482A1 Chds as modifiers of the p53 pathway and methods of use
12/12/2002CA2449479A1 Map3ks as modifiers of the p53 pathway and methods of use
12/12/2002CA2449466A1 Peripheral blood fibrocytes differentiation pathway and migration to wound sites
12/12/2002CA2449426A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
12/12/2002CA2449425A1 Slc2as as modifiers of the p53 pathway and methods of use
12/12/2002CA2449289A1 Gfats as modifiers of the p53 pathway and methods of use
12/12/2002CA2449281A1 Prmts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449275A1 Dgks as modifiers of the p53 pathway and methods of use
12/12/2002CA2449270A1 Pibs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449267A1 Hs2sts as modifiers of the p53 pathway and methods of use
12/12/2002CA2449221A1 P5crs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449206A1 Cads as modifiers of the p53 pathway and methods of use
12/12/2002CA2449175A1 Use of methylnaltrexone to treat immune suppression
12/12/2002CA2449136A1 Igs as modifiers of the p53 pathway and methods of use
12/12/2002CA2449024A1 Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
12/12/2002CA2448656A1 Compositions and methods for inhibiting bone resorption
12/12/2002CA2448606A1 Nucleic acid-associated proteins
12/12/2002CA2448427A1 Molecules and methods for inhibiting shedding of kim-1
12/12/2002CA2448384A1 Transcriptional regulator of genes involved in the control of cell growth or cell proliferation. use of said regulator as a therapeutic or diagnostic agent
12/12/2002CA2448382A1 Use of hepcidin as a regulator of iron homeostasis
12/12/2002CA2448282A1 Slc7s as modifiers of the p53 pathway and methods of use
12/12/2002CA2448250A1 Limks as modifiers of the p53 pathway and methods of use
1 ... 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 ... 1151